SOURCE: World Street Fundamentals

May 12, 2011 09:17 ET

Emerging Economies Driving New Growth -- Industry Report Featuring Stryker Corporation and Boston Scientific Corporation

HONG KONG--(Marketwire - May 12, 2011) - Today, released its industry report highlighting Stryker Corporation (NYSE: SYK) and Boston Scientific Corporation (NYSE: BSX). Full fundamental and technical analysis is available at

The global pharmaceutical market is expected to experience wide changes, with trends growing towards the Asia-Pacific region. A favorable regulatory environment has started to emerge in India, China, Malaysia, South Korea and Indonesia; drawing the attention of larger API product providers. This new competition within an already fast-paced economy has closed the gap between product cost and disposable income of consumers -- a change that is expected to drive long-term growth within the global marketplace.

Global pharmaceutical market sales are expected to grow at a 4 - 7% compound annual growth rate (CAGR) through 2013, largely driven via growing access to health-care in emerging economic regions. Short-term growth within the sector will be fueled by the US market, as it remains the largest pharmaceutical market in the world. A large focus on R&D in biotechnology, special drugs and generic drugs will remain a strong catalyst to meet 2011 targets of $315 billion dollar in sales volume within the United States alone.

World Street Fundamentals has highlighted Stryker for its focus on providing orthopaedic implants, as well as medical and surgical equipment. It has two segments: Orthopaedic Implants and MedSurg Equipment. Its products include implants used in joint replacement, trauma and spinal surgeries; surgical equipment and surgical navigation systems. The entire report on Stryker Corporation (NYSE: SYK) is available here:

World Street has highlighted Boston Scientific for its business as a worldwide developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2010, the Company's products were offered for sale by seven business groups: CRM, Cardiovascular, including International Cardiology and Peripheral Interventions businesses; Electrophysiology; Endoscopy; Urology/Women's Health; Neuromodulation, and Neurovascular. The entire report on Boston Scientific Corporation (NYSE: BSX) is available here:

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information